Guardant Health Q2 revenue up 44% to $335M; raises 2026 guidance to $1.34-1.36B

Guardant Health, Inc.

Q2 revenue $335.0M (+44% YoY); Oncology $219.1M (+38%), Screening $52.9M (+258%).
Net loss $120.1M ($0.90/share); non-GAAP net loss $56.2M ($0.42/share).
2026 revenue guidance raised to $1.34-1.36B (prior $1.30-1.32B), growth 36-38%.
Screening revenue guidance raised to $218-230M; Shield volume 270k-285k tests.
FDA approved Guardant360 Liquid CDx; Shield included in ACS guidelines, UnitedHealth coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.